コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 or therapy, resuscitated cardiac arrest, and sustained ventricular tachycardia).
2 0% nonsustained ventricular tachycardia, 10% sustained ventricular tachycardia).
3 ached the composite outcome (46 deaths and 9 sustained ventricular tachycardia).
4 8 of 10 patients and no patients died or had sustained ventricular tachycardia.
5 istory of advanced atrioventricular block or sustained ventricular tachycardia.
6 rdioversion/defibrillation; or 3) documented sustained ventricular tachycardia.
7 odel mice and in heart failure patients with sustained ventricular tachycardia.
8 The most common adverse event (n=6) was sustained ventricular tachycardia.
9 ventricular fibrillation, or polymorphic or sustained ventricular tachycardia.
10 ent experienced cardiac arrest and three non-sustained ventricular tachycardia.
11 ained ventricular tachycardia, and inducible sustained ventricular tachycardia.
12 f healing canine infarcts were mapped during sustained ventricular tachycardia.
13 are independently associated with inducible sustained ventricular tachycardia.
14 en patients with and those without inducible sustained ventricular tachycardia.
15 coronary artery disease will have inducible sustained ventricular tachycardia.
16 ventricular systolic impairment (6%) and non-sustained ventricular tachycardia (31%) at baseline simi
17 uns of nonsustained ventricular tachycardia, sustained ventricular tachycardia, aborted sudden cardia
19 duced pause-dependent ventricular ectopy and sustained ventricular tachycardia after acute myocardial
20 iac death (SCD) and ventricular fibrillation/sustained ventricular tachycardia after cardiac implanta
21 is a noninvasive marker of the substrate of sustained ventricular tachycardia after myocardial infar
22 2)-adrenergic receptor blocker and developed sustained ventricular tachycardia after transverse aorti
23 zard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009),
24 f successful ablation sites in patients with sustained ventricular tachycardia and coronary artery di
25 cluded mortality, resuscitated sudden death, sustained ventricular tachycardia and heart failure.
26 s without arrhythmias; however, they develop sustained ventricular tachycardia and sudden cardiac dea
27 ntable cardioverter-defibrillator shock, and sustained ventricular tachycardia) and end-stage heart f
28 shock, nonfatal ventricular fibrillation, or sustained ventricular tachycardia); and a composite of H
29 ventricular arrhythmic episode; 3/106 (2.8%) sustained ventricular tachycardia, and 20/106 (18.9%) no
30 tricular contractions, 10 (25%) patients for sustained ventricular tachycardia, and 7 (17.5%) patient
31 , 5 patients died suddenly, 9 had documented sustained ventricular tachycardia, and another 5 had app
32 e of MAREs, defined as sudden cardiac death, sustained ventricular tachycardia, and appropriate impla
33 ns at presentation, 5-year incidence of SCD, sustained ventricular tachycardia, and emerging Class I
34 AACEs included postdischarge sudden death, sustained ventricular tachycardia, and ventricular fibri
35 ts (18%) experienced the primary VA outcome (sustained ventricular tachycardia, appropriate implantab
36 ntricular arrhythmia (sudden cardiac arrest, sustained ventricular tachycardia, appropriate implantab
37 cular events (heart failure hospitalization, sustained ventricular tachycardia/appropriate shock, hea
38 n=33) SCD, and 98 (24.6%) experienced SCD or sustained ventricular tachycardia as the first event.
39 eath in patients with hemodynamically stable sustained ventricular tachycardia complicating coronary
41 left ventricular dysfunction, and inducible sustained ventricular tachycardia during electrophysiolo
42 -/-) mice vs. 0/10 Kcne3(+/+) mice exhibited sustained ventricular tachycardia during reperfusion (P<
43 ally unique manner to those who present with sustained ventricular tachycardia (e.g., adenosine-sensi
44 tricular conduction abnormalities, inducible sustained ventricular tachycardia, enrollment as an inpa
45 receiving the ICD previously had documented sustained ventricular tachycardia/fibrillation or cardia
46 mposite of malignant ventricular arrhythmia (sustained ventricular tachycardia/fibrillation), heart f
47 the following events: sudden cardiac death, sustained ventricular tachycardia/fibrillation, or appro
48 rcuits in the EBZ of infarcted hearts during sustained ventricular tachycardias (>30 seconds, n=17 ep
49 : 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) a
50 (HR) 1.9 (95% CI: 1.1-3.4)], history of non-sustained ventricular tachycardia [HR 1.7 (95% CI: 1.1-2
51 as ventricular fibrillation in 157 patients, sustained ventricular tachycardia in 236, both ventricul
52 t enhancer Bay Y5959 prevented initiation of sustained ventricular tachycardia in 7 of 14 experiments
53 cations occurred in nine patients, including sustained ventricular tachycardia in five, myocardial in
54 Flecainide prevented catecholamine-induced sustained ventricular tachycardia in RyR2(R4496C+/-) mic
55 h (SCD) and VAs (ventricular fibrillation or sustained ventricular tachycardia) in patients with coro
56 infarcts with a multielectrode array during sustained ventricular tachycardia induced by programmed
58 tcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacema
59 ing, and the hemodynamic consequences of non-sustained ventricular tachycardia is also established.
60 tory of unexplained syncope or of documented sustained ventricular tachycardia is associated with a h
63 plantable cardiac defibrillator shock (n=4), sustained ventricular tachycardia (n=1), or sudden death
65 D because of ventricular fibrillation (n=6), sustained ventricular tachycardia (n=14), and appropriat
67 th (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left v
68 , cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature v
69 ventricular ectopic beats, nonsustained and sustained ventricular tachycardia of left bundle branch
70 mary end point was a composite of documented sustained ventricular tachycardia or appropriate ICD the
71 le sex (P < .0001), presenting arrhythmia of sustained ventricular tachycardia or fibrillation (P < .
73 elevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard
74 .003) predominately due to the occurrence of sustained ventricular tachycardia or need of resuscitati
75 rtic surgery), arrhythmic events (defined as sustained ventricular tachycardia or sudden cardiac deat
76 nical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wav
77 vo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrill
78 assessed arrhythmic events (nonsustained or sustained ventricular tachycardia or ventricular fibrill
79 s during P2, and suppressed the incidence of sustained ventricular tachycardia or ventricular fibrill
80 r death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrill
81 ariate predictors for arrhythmic end points (sustained ventricular tachycardia or ventricular fibrill
82 defibrillator to treat an initial episode of sustained ventricular tachycardia or ventricular fibrill
86 d sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implan
87 ignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock
88 den cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or arrhythmogenic syn
89 lure hospitalization, recurrent myocarditis, sustained ventricular tachycardia, or death) with ESC di
90 s or ablation for confirmed sustained or non-sustained ventricular tachycardia, or high burden of pre
91 defined as sudden cardiac death, documented sustained ventricular tachycardia, or non-fatal cardiac
92 nce of nonsustained ventricular tachycardia, sustained ventricular tachycardia, or supraventricular t
93 orphic ventricular ectopy (in the absence of sustained ventricular tachycardia) originating from the
94 fatal episode of ventricular fibrillation or sustained ventricular tachycardia requiring external car
95 ntable cardioverter-defibrillator therapies, sustained ventricular tachycardia, resuscitated cardiac
96 ath/life-threatening ventricular arrhythmia (sustained ventricular tachycardia, resuscitated sudden c
97 me (composite measure of first occurrence of sustained ventricular tachycardia/resuscitated sudden ca
98 or their ability to abolish pace-induced and sustained ventricular tachycardia (SVT) or prevent induc
99 or [ICD] shock or antitachycardia pacing, or sustained ventricular tachycardia terminated by emergenc
100 tely 5% of patients with PVCs have inducible sustained ventricular tachycardia that behaves in an ide
101 econdary prevention (after cardiac arrest or sustained ventricular tachycardia), the devices were act
102 tachycardia storm, appropriate ICD shock, or sustained ventricular tachycardia treated by medical int
103 sudden cardiac arrest or death, spontaneous sustained ventricular tachycardia, ventricular fibrillat
104 primary end point was sudden cardiac death, sustained ventricular tachycardia, ventricular fibrillat
105 r arrhythmia (resuscitated cardiac arrest or sustained ventricular tachycardia/ventricular fibrillati
106 However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillati
107 esigned to assess the predictive accuracy of sustained ventricular tachycardia/ventricular fibrillati
108 for death in early follow-up (0-3 hrs after sustained ventricular tachycardia/ventricular fibrillati
109 as to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillati
110 ist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillati
111 h acute myocardial infarction complicated by sustained ventricular tachycardia/ventricular fibrillati
112 n (DHF/HTx/VAD); and 3) sudden cardiac death/sustained ventricular tachycardia/ventricular fibrillati
113 for life-threatening arrhythmias, defined as sustained ventricular tachycardia (VT) >/=240 beats/min
117 al activity contributes to the initiation of sustained ventricular tachycardia (VT) as reflected in i
121 lectrophysiologic testing revealed inducible sustained ventricular tachycardia (VT) in six of the eig
122 ngation (> or = 180 ms) is a risk marker for sustained ventricular tachycardia (VT) late after repair
124 st one prior catheter ablation procedure for sustained ventricular tachycardia (VT) or nonsustained V
126 ction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fi
127 g and radiofrequency ablation of postinfarct sustained ventricular tachycardia (VT) remain one of the
128 thetic nerve activity (SNA) increases during sustained ventricular tachycardia (VT), and the magnitud
129 rhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de p
130 is discovered on the rate of inducibility of sustained ventricular tachycardia (VT), arrhythmic event
131 d point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac d
135 was defined as sudden cardiac death (SCD) or sustained ventricular tachycardia (VT)/ventricular fibri
136 ) sudden cardiac arrest; 2) nonsustained and sustained ventricular tachycardia (VT); 3) pre-excitatio
137 objective of this study was to determine why sustained ventricular tachycardias (VT) sometimes stop w
139 To determine the mechanisms of resetting, sustained ventricular tachycardia was induced in dogs wi
142 nt occurrences of SCD (fatal or aborted) and sustained ventricular tachycardia were recorded, as were
144 atal ventricular fibrillation and those with sustained ventricular tachycardia with syncope or systol
145 substrate of sudden death resembled that of sustained ventricular tachycardia, with pulmonary regurg